NASDAQ · LITSHealthcarePharmaceuticals

Lite Strategy financials

$1.38+1.10%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ4 '26
Jun 30
Q3 '26
Mar 31
Q2 '26
Dec 31
Q1 '26
Sep 30
Revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Gross margin————
Operating income-$11.4M-$21.6M-$3.4M-$3.7M
Net income-$13.0M-$23.7M-$30.8M-$3.6M
Net margin————
Diluted EPS$-0.36$-0.66$-0.82$-0.12
EBITDA-$11.4M-$21.6M-$3.4M-$3.1M
Operating cash flow-$1.2M-$1.5M-$1.9M-$4.5M
Free cash flow-$1.2M-$1.5M-$1.9M-$4.5M
Diluted shares35.7M35.7M37.4M29.5M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30
Cash & equivalents$5.7M$7.5M$8.8M$10.1M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00
Total assets$42.7M$57.8M$82.9M$113.3M
Total liabilities$1.1M$952.0K$1.1M$1.1M
Shareholders' equity$41.6M$56.8M$81.8M$112.3M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology